Insilicos
Insilico Medicine Receives $800K Investment as Prelude to Larger Deal
The $800,000 is part of a convertible bridge note agreement that could provide Insilico at least $4M in a next funding round, based on certain milestones.
Insilicos, U of Washington Form Joint Venture to Market Cloud-Based Version of Rosetta Software
Premium
Insilicos, a Seattle-based biomedical software company, is partnering with the University of Washington to market a cloud-based version of the university’s Rosetta protein and molecular modeling software.
The plan, which the agency made public on Jan. 19, detailed a number of draft guidances FDA intends to put out this year; but it's the items that it declined to address, like the development of a new Class IIb device category, that could be the most significant.
Movers & Shakers: Dec 24, 2010
Premium
Peter Bergquist, John Fletcher, Lars Utterman, David Weber, Jeff Howbert
Singulex Receives US Patent for Cardiovascular Biomarker Assay, Begins Planning FDA Submission
Premium
The patent follows on one the company received last year for the Erenna platform itself, and comes as it begins efforts to develop the assay as a clinical diagnostic that it hopes to submit for US Food and Drug Administration approval within the next two years.
Feb 6, 2009